New Therapies for Dedifferentiated Papillary Thyroid Cancer

New Therapies for Dedifferentiated Papillary Thyroid Cancer

The number of thyroid cancers is increasing. Standard treatment usually includes primary surgery, thyroid-stimulating hormone suppressive therapy, and ablation of the thyroid remnant with radioactive iodine (RAI). Despite the generally good prognosis of thyroid carcinoma, about 5% of patients will d...

Full description

Bibliographic Details
Main Authors: Poupak Fallahi, Valeria Mazzi, Roberto Vita, Silvia Martina Ferrari, Gabriele Materazzi, David Galleri, Salvatore Benvenga, Paolo Miccoli, Alessandro Antonelli
Format: Article
Language:English
Published: MDPI AG 2015-03-01
Series:International Journal of Molecular Sciences
Subjects:
dedifferentiated thyroid cancer
radioiodine
papillary thyroid carcinoma
RET (REarranged during Transfection)
BRAF (B-Raf proto-oncogene, serine/threonine kinase)
RAS (Rat Sarcoma)
vascular endothelial growth factor receptor 2
vandetanib
cabozantinib
sorafenib
Online Access:http://www.mdpi.com/1422-0067/16/3/6153

Internet

http://www.mdpi.com/1422-0067/16/3/6153

Similar Items